# Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

> **NCT04951492** · PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 2 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Prostate Adenocarcinoma

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT04951492
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-09
- **Primary completion:** 2023-10-15
- **Final completion:** 2023-10-15
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Withdrawal of funding
- **Last updated:** 2025-01-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04951492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04951492, "Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04951492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*